Nanoparticulate delivery systems for antiviral drugs.
Nanomedicine opens new therapeutic avenues for attacking viral diseases and for improving treatment success rates. Nanoparticulate-based systems might change the release kinetics of antivirals, increase their bioavailability, improve their efficacy, restrict adverse drug side effects and reduce treatment costs. Moreover, they could permit the delivery of antiviral drugs to specific target sites and viral reservoirs in the body. These features are particularly relevant in viral diseases where high drug doses are needed, drugs are expensive and the success of a therapy is associated with a patient's adherence to the administration protocol. This review presents the current status in the emerging area of nanoparticulate delivery systems in antiviral therapy, providing their definition and description, and highlighting some peculiar features. The paper closes with a discussion on the future challenges that must be addressed before the potential of nanotechnology can be translated into safe and effective antiviral formulations for clinical use.
Dipartimento di Scienze Cliniche e Biologiche, Università degli Studi di Torino, Orbassano Torino, Italy.
David
D
Lembo
Roberta
R
Cavalli
D000998:Antiviral Agents / Q000008:administration & dosage* / Q000737:chemistry* / Q000493:pharmacokinetics / Q000627:therapeutic use; D004333:Drug Administration Routes; D004334:Drug Administration Schedule; D016503:Drug Delivery Systems / Q000379:methods; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D053758:Nanoparticles / Q000737:chemistry; D036103:Nanotechnology / Q000379:methods*; D014777:Virus Diseases / Q000517:prevention & control / Q000628:therapy
D000998:Antiviral Agents